Immunovant Inc (IMVT)

Currency in USD
15.46
-0.27(-1.72%)
Closed·
After Hours
15.00-0.46(-2.98%)
·
IMVT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IMVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.1616.09
52 wk Range
12.7234.47
Key Statistics
Prev. Close
15.73
Open
15.66
Day's Range
15.16-16.09
52 wk Range
12.72-34.47
Volume
646.9K
Average Volume (3m)
1.26M
1-Year Change
-45.02%
Book Value / Share
4.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
41.64
Upside
+169.36%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Immunovant Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Immunovant Inc Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant Inc SWOT Analysis


Pioneering Treatment
Immunovant's novel anti-FcRn therapy shows promise for autoimmune diseases, particularly Graves' disease, with potential for best-in-class efficacy
Market Potential
Explore the substantial opportunity in Graves' disease, with an estimated 20,000 high-need patients diagnosed annually in the US
Analyst Optimism
Price targets range from $36 to $58, suggesting significant upside potential despite recent stock decline. Average target stands at $57
Strategic Expansion
Delve into Immunovant's ambitious plan to target 10 indications by 2026, diversifying risk and expanding market potential
Read full SWOT analysis

Compare IMVT to Peers and Sector

Metrics to compare
IMVT
Peers
Sector
Relationship
P/E Ratio
−6.4x−4.0x−0.5x
PEG Ratio
0.14−0.010.00
Price/Book
3.7x2.5x2.6x
Price / LTM Sales
-151.9x3.3x
Upside (Analyst Target)
182.9%196.4%43.5%
Fair Value Upside
Unlock6.5%6.8%Unlock

Analyst Ratings

12 Buy
4 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 41.64
(+169.36% Upside)

Earnings

Latest Release
Aug 08, 2025
EPS / Forecast
-- / -0.6962
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMVT Income Statement

People Also Watch

247.45
AVAV
-4.68%
16.42
ARWR
+2.24%
109.55
INSM
+0.23%
35.39
APGE
-1.69%

FAQ

What Stock Exchange Does Immunovant Trade On?

Immunovant is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Immunovant?

The stock symbol for Immunovant is "IMVT."

What Is the Immunovant Market Cap?

As of today, Immunovant market cap is 2.64B.

What Is Immunovant's Earnings Per Share (TTM)?

The Immunovant EPS (TTM) is -2.73.

When Is the Next Immunovant Earnings Date?

Immunovant will release its next earnings report on 30 Oct 2025.

From a Technical Analysis Perspective, Is IMVT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Immunovant Stock Split?

Immunovant has split 0 times.

How Many Employees Does Immunovant Have?

Immunovant has 362 employees.

What is the current trading status of Immunovant (IMVT)?

As of 09 Aug 2025, Immunovant (IMVT) is trading at a price of 15.46, with a previous close of 15.73. The stock has fluctuated within a day range of 15.16 to 16.09, while its 52-week range spans from 12.72 to 34.47.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.